Innovators Under 35
INNOVATIVE Entrepreneurs
E3. Rachel Haurwitz, 32
Caribou
Biosciences
Overseeing the commercialization of the
promising gene-editing method called CRISPR.
Rachel Haurwitz
quickly went from lab rat to CEO at the center of the frenzy over CRISPR, the
breakthrough gene-editing technology. In 2012 she’d been working at Jennifer
Doudna’s lab at the University of California, Berkeley, when it made a
breakthrough showing how to edit any DNA strand using CRISPR. Weeks later,
Haurwitz traded the lab’s top-floor views of San Francisco Bay for a
sub-basement office with no cell coverage and one desk. There she became CEO of
Caribou Biosciences, a spinout that has licensed Berkeley’s CRISPR patents and
has made deals with drug makers, research firms, and agricultural giants like
DuPont. She now oversees a staff of 44 that spends its time improving the core
gene-editing technology. One recent development: a tool called SITE-Seq to help
spot when CRISPR makes mistakes.
—Antonio Regalado
—Antonio Regalado
MIT TECHNOLOGY REVIEW
No comments:
Post a Comment